Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Account Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Account Payables for 3 consecutive years, with -$1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 237.56% to -$1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$5.6 million, a 123.36% decrease, with the full-year FY2024 number at $17.9 million, up 748.89% from a year prior.
  • Change in Account Payables was -$1.5 million for Q3 2025 at Inhibrx Biosciences, down from -$600000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $17.4 million in Q2 2024 to a low of -$3.1 million in Q4 2024.
  • A 3-year average of $1.9 million and a median of -$450000.0 in 2024 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 71.75% in 2024, then tumbled 237.56% in 2025.
  • Inhibrx Biosciences' Change in Account Payables stood at $2.9 million in 2023, then crashed by 207.18% to -$3.1 million in 2024, then soared by 51.3% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Change in Account Payables are -$1.5 million (Q3 2025), -$600000.0 (Q2 2025), and -$353000.0 (Q1 2025).